Shire PLC  

(Public, LON:SHP)   Watch this stock  
Find more results for SHP
5,230.00
-35.00 (-0.66%)
Jul 3 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 5,180.00 - 5,290.00
52 week 3,448.28 - 5,755.00
Open 5,250.00
Vol / Avg. 489,301.00/1.09M
Mkt cap 30.81B*
P/E 14.00
Div/yield 12.51*
EPS 3.74*
Shares 591.89M
Beta     -
Inst. own     -
*GBP
Jul 23, 2015
Q2 2015 Shire PLC Earnings Release - 8:00AM GMT+1 - Add to calendar
Jun 15, 2015
Shire PLC at Citi European Healthcare Conference
Jun 2, 2015
Shire PLC at Jefferies Global Healthcare Conference
May 7, 2015
Shire PLC at Deutsche Bank Health Care Conference
Apr 30, 2015
Q1 2015 Shire PLC Earnings Call
Apr 30, 2015
Q1 2015 Shire PLC Earnings Release
Apr 28, 2015
Shire PLC Annual Shareholders Meeting
  

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin 27.81% 54.47%
Operating margin 31.89% 28.20%
EBITD margin - 41.79%
Return on average assets 10.60% 29.88%
Return on average equity 18.77% 46.80%
Employees 5,016 -
CDP Score - 91 B

Address

5 Riverwalk Citywest Business Campus, Dublin 24
DUBLIN,
Ireland
+353-1-4297700 (Phone)
+353-1-4297701 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance

Description

Shire plc is a biopharmaceutical company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other specialty conditions. The Company commercializes its products in the areas of Neuroscience, Gastrointestinal (GI), Rare Diseases and Other therapeutic areas. The Company’s products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSE VUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), EQUASYM (methylphenidate hydrochloride) modified release (XL), BUCCOLAM, LIALDA (mesalamine)/ MEZAVANT(mesalazine), PENTASA (mesalamine), RESOLOR (prucalopride), REPLAGAL (agalsidase alfa), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), CINRYZE C1 esterase inhibitor (human), FOSRENOL (lanthanum carbonate), XAGRID/ AGRYLIN (anagrelide hydrochloride) and PLENADREN (modified release hydrocortisone).

Officers and directors

Flemming Ornskov M.D. Chief Executive Officer, Executive Director
Age: 57
Jeffrey Poulton Chief Financial Officer, Director
Age: 47
Ginger Gregory Chief Human Resource Officer
Mark J. Enyedy Interim General Counsel, Head of Corporate Development
Age: 51
Phil J. Vickers Head of Research and Development
Age: 55
Susan Saltzbart Kilsby Non-Executive Chairman of the Board
Age: 56
David J. Kappler Senior Independent Non-Executive Deputy Chairman of the Board
Age: 67
Dominic Blakemore Non-Executive Independent Director
Age: 45
William Burns Non-Executive Independent Director
Age: 67
Steven H. Gillis Ph.D. Non-Executive Independent Director
Age: 63